wellrank.ai
Shapely logo

Shapely

First cited by AI Jun 12, 2026
shapelyevents.com

Surfaced organically in AI answers about glp-1 weight loss. Not yet profiled.

AI Visibility

Visibility trend

GLP-1 weight loss, daily share of AI answers mentioning Shapely, through Jun 13, 2026.

8.3%

Avg position when mentioned: 2.0

By engine

Where Shapely is strong, and where it is invisible.

  • Perplexity
    33.3%

Mention sentiment

Tone of AI mentions across all tracked answers.

  • 0 positive mentions
  • 1 neutral
  • 0 mixed or cautious

Recent AI answers mentioning Shapely

PerplexityJun 13, 2026, 11:01 UTC
What is the cheapest legit way to get semaglutide online?

The cheapest legit way to get semaglutide online is usually to use an FDA-approved brand through the manufacturer’s savings program if you qualify, or a patient assistance program if you’re uninsured or underinsured.[1] For many people, that beats cash-pay telehealth pricing and reduces the risk of counterfeit or unsafe products.[1][3][5] If you have private/commercial insurance, Novo Nordisk’s Ozempic savings card can bring the cost to as little as $25 for a 1-, 2-, or 3-month supply for eligible patients.[1] If you’re uninsured or underinsured, Novo Nordisk’s patient assistance program may provide Ozempic or Rybelsus at no cost if you meet eligibility criteria.[1] If you need a cash-pay online option, telehealth services like Shapely advertise compounded semaglutide starting at $99/month, and WeightWatchers lists self-pay Ozempic/Wegovy starting at $199/month.[2][5] Sesame can connect you to an online prescriber for Ozempic, Wegovy, or Rybelsus, but the medication cost depends on the pharmacy and whether you qualify for a brand-name prescription.[3] For the lowest legitimate price, I’d check in this order: Manufacturer savings/patient assistance first.[1] Insurance prior authorization + copay card if you have commercial insurance.[1] Reputable telehealth with an FDA-approved prescription if you’re paying cash and need online convenience.[2][3][5] A caution: “compounded semaglutide” is not the same as brand-name semaglutide and may not carry the same FDA-approved formulation, so the cheapest option is not always the safest or most reliable.[2][4] If you want, I can compare the cheapest legitimate options by your situation: insured, uninsured, or weight-loss vs. diabetes.

Mentioned in position 2 of 4

Read full answer with sources →

Public AI visibility history

Daily rank of Shapely on our buyer intent questions, per category. A dash means the engines did not cite Shapely at all that day. This record is permanent.

CategoryJun 11Jun 12Jun 13
GLP-1 weight loss#33

TL;DR

Shapely (shapelyevents.com) appears to be a telehealth or wellness platform that has surfaced in AI-generated answers related to GLP-1 and semaglutide weight loss, though it has not yet received a full public profile on WellRank. According to the WellRank index, Shapely currently holds the tenth position in GLP-1 weight loss AI answer visibility with an 8% share, placing it in early-stage AI presence territory. The single AI mention captured in the WellRank corpus carries a neutral tone, suggesting the brand is being cited informationally rather than recommended with enthusiasm.

Company Overview

Shapely operates in the weight loss and wellness space, with AI engines surfacing its content in the context of GLP-1 medications such as semaglutide. Its website is shapelyevents.com, though AI sources have also cited getshapely.com in answers about the brand, as seen in references to semaglutide medication information. Founding details, headquarters location, and ownership structure are not publicly disclosed. The business model, whether direct-to-consumer telehealth, medication access facilitation, or a hybrid wellness program, is not clearly established in widely available public sources.

Product Features

  • GLP-1 medication guidance or access, including content around semaglutide
  • Weight loss program or coaching component, inferred from brand positioning
  • Online or telehealth-style delivery model, based on AI engine context
  • Informational resources on GLP-1 weight loss medications

Target Market

Shapely appears to target adults seeking weight loss support, particularly those interested in or already using GLP-1 medications like semaglutide. Geography is not publicly confirmed, though the telehealth and medication-access framing suggests a US-focused audience. The brand sits in a category that typically serves people with obesity or weight-related health concerns who are exploring pharmacological options alongside lifestyle changes.

Buyer Personas

  • An adult with obesity who is researching semaglutide or other GLP-1 medications and wants guidance on access and cost.
  • A cost-conscious patient comparing telehealth weight loss programs and looking for affordable medication pathways, similar to those comparing options on SingleCare's cheapest semaglutide roundup.
  • A wellness-motivated individual who has heard about GLP-1 drugs and wants a structured program rather than a standalone prescription.
  • A returning Weight Watchers-style program user who is now interested in combining behavioral support with medical weight loss tools.

Funding & Performance

Funding stage, investment history, and company valuation are not publicly disclosed. There is no widely available information about Shapely's revenue scale, headcount, or investor backing.

Recent Developments

Shapely has organically appeared in AI-generated answers about GLP-1 weight loss, which suggests its content or offerings have gained enough relevance to be indexed by AI engines in this competitive category. The brand has not yet been the subject of notable press coverage or publicly announced product launches that are widely verifiable. Its emergence in AI answer rankings, even at a nascent 8% visibility, reflects a broader industry trend of smaller telehealth and wellness brands gaining traction as interest in semaglutide and related medications continues to grow.

Competitive Landscape

Based on WellRank co-mention data, Shapely is most frequently cited alongside WeightWatchers, Sesame, and Novo Nordisk in AI-generated answers about GLP-1 weight loss. This places it in direct conceptual competition with established weight loss programs that have added GLP-1 medication components, as well as transparent-pricing telehealth marketplaces. Against these better-known brands, Shapely's 8% AI visibility share reflects early-stage competitive presence rather than category leadership.

Shapely vs the brands AI recommends alongside it

The real competitive set in GLP-1 weight loss: brands the engines name in the same answers, ranked on the latest day.

BrandRankAI visibility
Shapely logo
ShapelyThis brand
#33
8.3%
Novo Nordisk logo
Novo Nordisk

1 shared answers

#6
25.0%
Sesame logo
Sesame

1 shared answers

#14
8.3%
WeightWatchers logo
WeightWatchers

1 shared answers

#4
25.0%

Email me when overtakes Shapely

One email the day the ranks flip. Nothing else.

User Sentiment

The WellRank corpus contains one AI mention of Shapely, which is classified as neutral in tone, with zero positive and zero mixed or cautious signals recorded. This suggests AI engines are referencing the brand as a factual data point in weight loss medication answers rather than actively endorsing or questioning it. Public consumer sentiment is not yet established in widely available reviews or coverage, making it difficult to assess broader user perception at this time.

Pricing

Pricing for Shapely's programs or services is not published in any widely available public source and is not publicly disclosed.

Sources cited around Shapely

The sites engines cite in answers mentioning this brand. Win these, win the answer.

Track Shapely weekly

One email a week: rank moves, new competitors, and the answers that changed. No noise.

Work at Shapely? Get your AI Visibility Audit.

See every buyer intent question your customers ask AI, which ones you are losing, who wins them instead, and the exact sources driving those answers. You will finally understand your buyer intent and what Propel would do to win it.

Shapely: AI visibility report | WellRank